Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Lecanemab is an experimental humanised antibody that targets amyloid beta aggregates known as protofibril. The drug was developed as part of a collaboration between Eisai and BioArctic. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.